Genova BioMed Invests in Jiabao Renhe, a Leading Provider of Genetic Testing for Assisted Reproduction, Accelerating Its Niche Market Expansion

Recently, VCBeat (WeChat: vcbeat) learned that GTJA Investment has completed its investment in Peking Jabrehoo Med Tech Co., Ltd., a leading enterprise in the field of genetic testing for assisted reproduction, continuing to accelerate its layout in various segments of the genetic testing industry.

Zhou Zhiliang, Executive Partner at GTJA Investment Group, introduced that Jabrehoo, as a niche industry leader in the field of genetic testing for assisted reproduction in China, was among the first domestic companies to introduce high-throughput sequencing technology into the assisted reproduction sector. Its business scope includes preimplantation genetic screening (PGS)/diagnosis (PGD) testing, embryo genome sequencing and analysis, miscarriage tissue analysis, preconception genetic testing, infertility genetic testing, and the research and development of medical devices for assisted reproduction. With a rich product pipeline and high technical barriers, the company covers the entire closed-loop industrial chain of reproductive health and fertility.

Currently, Jabrehoo’s business covers more than 70% of the reproductive medicine centers in mainland China that are nationally approved to conduct preimplantation genetic diagnosis (PGD). The company has established joint laboratories in Southeast Asia and the United States and possesses the world’s largest embryo database.

“GTJA Investment has maintained a continuous focus on gene technology, an emerging technical field, particularly on its applications across various sub-sectors. Assisted reproductive technology (ART) is a fundamental necessity in China, with a potential market size reaching RMB 100 billion. PGD/PGS technologies can increase the success rate of ART from 40% to over 70%, making them the most promising technologies and applications in the field of assisted reproduction, as recognized internationally. Jabrehoo is a leading domestic provider of genetic testing services for assisted reproduction, and we are highly optimistic about the company’s future development,” disclosed Zhou Zhiliang.

Peking Jabrehoo Med Tech Co., Ltd. was established in June 2011. As a national high-tech enterprise headquartered in Beijing, it operates a 4,000-square-meter facility in the Beijing Daxing Biomedical Industry Base, comprising an R&D center, GMP-certified production workshops, and a training base. The company holds multiple invention patents and is internationally leading in the field of genetic testing for assisted reproduction.

As a pioneer and leader in providing next-generation sequencing (NGS) integrated solutions in the field of assisted reproduction, Peking Jabrehoo Med Tech Co., Ltd. offers professional equipment, consumables, diagnostic reagents, bioinformatics analysis platforms, and specialized services covering genetic screening and diagnosis. Meanwhile, the company is also dedicated to the development, production, and market promotion of products and technologies related to assisted reproduction and maternal and child health.

Fei Jia, CEO of Jabrehoo, introduced the company’s industry position and core competitiveness in the field of preimplantation genetic diagnosis/screening (PGD/PGS) for assisted reproduction. This, combined with HTGC Investment’s continuous investment layout in the industry ecosystem, its practical understanding of portfolio companies, and its philosophy and capability to foster long-term synergistic development with them, has laid a solid foundation for this partnership between the two parties.

Fei Jia stated, “In selecting investment partners, Peking Jabrehoo Med Tech Co., Ltd. prioritizes their understanding of the healthcare and biotechnology industries, as well as the potential for future synergy and mutual development. This investment reflects GTJA Investment’s insight and strategic vision in the healthcare and biotech sectors, and we fully endorse the investment philosophy advocated by the GTJA Investment team.”